IC₅₀ values (mean ±SD in μM) of <i><i>in vitro</i></i> DPPH-radical scavenging properties vs. ascorbic acid and antiinflammation propensities vs. indomethacin of the tes... by MohammedBashar Al-Qazzan (22439236)

Subjects:

3D and 2D pose of the docked Shikonin diagram displaying a variety of interactions with enzyme’s active region. by MohammedBashar Al-Qazzan (22439236)

Subjects:

Classification of inactive compounds. by MohammedBashar Al-Qazzan (22439236)

Subjects:

Active compounds identified as glyoxalase-I inhibitors. by MohammedBashar Al-Qazzan (22439236)

Subjects:

The inhibitory activity of the most active compounds against Glo-I enzyme with less than 50 µM. Their supportive corresponding docking values on two different protocols are display... by MohammedBashar Al-Qazzan (22439236)

Subjects:

3D and 2D pose of the docked Tolcapone diagram displaying a variety of interactions with enzyme’s active region. by MohammedBashar Al-Qazzan (22439236)

Subjects:

Schematic presentation <i>M</i>. <i>bovis</i> PG45 5′ nucleotidase and phylogenetic tree of its homologs. by Aga E. Gelgie (17661720)

Oligonucleotides used in this study. by Aga E. Gelgie (17661720)

“…In comparison to the parent strain, the 0690::Tn mutant displayed markedly reduced fitness, as evidenced by a significant decrease or even absence in post-challenge mycoplasma counts in murine and cow mammary tissues, respectively. …”

Data supporting the findings of this study. by Aga E. Gelgie (17661720)

“…In comparison to the parent strain, the 0690::Tn mutant displayed markedly reduced fitness, as evidenced by a significant decrease or even absence in post-challenge mycoplasma counts in murine and cow mammary tissues, respectively. …”

Impact of 5′ nucleotidase disruption on <i>M</i>. <i>bovis</i> growth phenotype in axenic conditions. by Aga E. Gelgie (17661720)

<i>M</i>. <i>bovis</i> 0690::Tn mutant failed to elicit the recruitment of neutrophils into milk spaces. by Aga E. Gelgie (17661720)

Loss of mammary fitness and virulence by <i>M</i>. <i>bovis</i> 0690::Tn mutant. by Aga E. Gelgie (17661720)

Open data. by Larissa Brazolotto Ferreira (17671168)

“…</p><p>Results</p><p>There was a significant decrease in BMD in the lumbar spine (1.107 ± 0.109 and 1.075 ± 0.112 g/cm²; <i><i>p</i></i> < 0.001), total body (1.135 ± 0.086 and 1.119 ± 0.085 g/cm²; <i><i>p</i></i> < 0.001), and total proximal femur over the six months of EBF compared to the values obtained from the same EBF group at 15 days postpartum (mean percentage decreases in BMD of −3.4 ± 3.7% (<i><i>p</i></i> < 0.001) in lumbar spine, −2.5 ± 3.4% (<i><i>p</i></i> < 0.001) in total proximal femur, and −1.7 ± 1.9% (<i><i>p</i></i> = 0.001) in total body). …”

Cell cycle analysis of A2780 cells following AGPAT3 overexpression. by Hadi Alizadeh (20854757)

I Optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

ANOVA for I optimal design of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

The kinetic release data of the optimized formula compared to drug suspension. by Randa Mohammed Zaki (21637175)

Composition of different formulations with their responses in I optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

The composition and validation of the optimized formula with its predicted responses according to I Optimal Design. by Randa Mohammed Zaki (21637175)

Mapping of transposon insertions in the selected mutants of <i>M</i>. <i>bovis</i> PG45. by Aga E. Gelgie (17661720)